Key result
Low-dose prasugrel (20 mg loading/3.75-5 mg maintenance) guided by platelet function testing provides predictable platelet inhibition with hemorrhagic complication rates similar to clopidogrel.
Why the study?
Prasugrel use is limited by an FDA boxed warning developed from cardiology cohorts with fixed dosing, while contemporary practice has diversified.
Does low-dose, platelet function-guided prasugrel provide ischemic protection with acceptable bleeding risk in neurointervention compared to standard therapy?
Does low-dose, platelet function-guided prasugrel provide ischemic protection with acceptable bleeding risk in neurointervention compared to standard therapy?
Platelet function-guided and dose-adjusted prasugrel therapy may offer a safer and effective alternative to fixed cardiology dosing in neurointerventional procedures.
No takes yet. Share an insight, caveat, or question.
Supports individualized prasugrel dosing in neurointerventional patients; challenges uniform application of the cardiology-derived FDA boxed warning.
Ibrahim et al. (2026) conducted a review in Neurointervention. Prasugrel vs. Clopidogrel was evaluated. Low-dose prasugrel (20 mg loading/3.75-5 mg maintenance) guided by platelet function testing provides predictable platelet inhibition with hemorrhagic complication rates similar to clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: